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Abstract
Background: Environmental asbestos exposure can cause the grave lung and pleura malignancies
with a high mortality rate, and it is also associated with increased rate of other organ malignancies.
Asbestos exposure can develop genotoxic effects and damage in the pleura and lungs.
Objective: In this study, we aimed to determine tumor suppressor gene (TSG) loss in genomic
DNA which was isolated from pleural fluid and blood samples of patients with Malignant Pleural
Mesothelioma (MPM) due to environmental asbestos exposure.
Design and patients: Prospective study of period from 2001 to 2003 in 17 patients with MPM.
Methods: A total of 12 chromosomal regions were researched by comparing genomic DNA
samples isolated from blood and pleural effusion (using PCR, and polyacrilamid gel electrophoresis
denaturizing), on 2 different chromosomes which have 9 different polymorphic determinants at 6q
and 3 different polymorphic determinants at 9p using molecular genetic methods on 13 patients
clinico-pathologically diagnosed MPM.
Results: Loss of Heterozygosity (LOH) was determined at D6S275 in one patient, at D6S301 in
another, at D6S474 in 2, at ARG1 in 2, at D6S1038 in 2 and at D6S1008 in 3 patients. In 7 (54%)
of the13 patients, we found LOH in at least one site. No LOH was determined at any informative
loci in 6 patients. Of the 13 patients, no investigated markers were determined at 9p.
Conclusion: In this study, genomic DNA samples obtained from MPM patients with asbestos
exposure revealed that they contained important genotoxic damage. We found no other study on
this subject at molecular level in pleural effusion either in Turkey or in the med-line literature. We
believe that this study will provide important support for other research into molecular-genetic
variations, both on this subject and other malignancies, and may also constitute a base for early
diagnosis and gene therapy research in the future.
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Background
Asbestos is a group of naturally-occurring silicate miner-
als. Silicates are the most abundant minerals (comprising
at least 30% of all minerals), which consist of various met-
als associated with silica and oxygen – the silicate part of
the molecule [1]. Asbestos, being an inorganic fibrous
mineral, is used in more than 3,000 areas of industry
because of its hyper-resistance to high temperatures, fric-
tion and chemical agents. An important form of exposure
to asbestos is also the inhalation of environmental asbes-
tos dust existing in the geological structures of the some
rural settlement areas of the Middle, South-eastern, East-
ern and Western Anatolia, and the Black Sea regions of
Turkey, since these so-called "white soils" were tradition-
ally used in rural areas to make a whitewash or stucco to
surface the walls, floors, and roofs of houses and also as a
substitute for baby powder and gripewater [1-4]. Environ-
mental asbestos exposure can cause Malignant Pleural
Mesothelioma (MPM), which may be fatal in a very short
period, and lung malignancy. It has been reported that the
high mortality rate and frequency of MPM, and lung can-
cer as an endemic disease, are remarkably increased in
these areas [1-3,5].
The incidence of MPM has increased world-wide over the
last 6 decades and it is assumed that this increase in trend
will continue until the year 2020 [6,7].
Mesothelioma develops 3.5 – 73 years (mean 37–40 yrs)
after asbestos exposure. Although generally the duration
of inhalation and the amount of asbestos dust inhaled are
thought to be responsible for the increased incidence of
MPM, sometimes an exposure of shorter periods (2–6
months) or lower doses are believed to cause mesotheli-
oma [2]. In a survey achieved in Turkey is reported that
the female-to-male ratio was 213:293. The mean age at
diagnosis was 56 years (range: 24–88 years), for both men
and women. In none of these cases was there a history of
occupational exposure to either asbestos or erionite. Six
percent of cases (30/506) were reported from the erionite
villages [8]. The frequency of malignant mesothelioma is
more than 20 times greater among asbestos industry
workers and people living in areas with environmental
asbestos contact. The frequency of Mesothelioma found
in autopsies of asbestos workers is approximately 3%,
which is 300 times higher than normal levels [1,2].
It is suggested that multiple, cumulative somatic genetic
events are required for tumorigenic conversion of a mes-
othelial cell [9]. Early studies with conventional banding
techniques revealed numerous karyotypic alterations in
most MMs [10]. Moreover, structural alterations in all
chromosomes, except chromosome Y, were detected
[6,11]. Changes consist of recurrent deletions of discrete
segments within chromosome arms 1p, 3p, 6q, 9p and
22q [10].
In this study, we aimed to determine LOH in a possible
tumor suppressor gene (TSG) region in the pleural fluid
samples of patients with MPM contracted, most probably,
because of exposure to environmental asbestos in the
Elazig Region of Turkey. And thus, the information
acquired from the investigation of MPM in molecular-
genetic level may also provide illuminated, important
somatic genetic mechanisms in both MPM and many
other cancer types [6,11].
Materials and methods
The study group consisted of 17 patients, 8 female (mean
age: 61.8 ± 9.8) and 9 male (mean age: 59.4 ± 9.1). The
mean environmental asbestos exposure was 27.3 ± 9.1
years. The diagnosis of MPM of all cases was clearly con-
firmed, both clinically and pathologically. All cases had
pleural effusion, had not been treated with cytotoxic
chemotherapy, had no malignancy other than MPM, and
did not smoke. In our study group, other possible causes
of MPM, such as contact with man-made synthetic min-
eral fiber, asbestiform minerals, beryllium and classical
collapse-therapy of tuberculosis or chronic calcified pleu-
ral tuberculosis were not determined.
2.1. The isolation of genomic DNAs
Genomic DNA isolation was obtained from the patients'
pleural effusion by phenol-chloroform methods, and
matched with genomic DNA obtained from peripheral
blood samples by standard methods. DNA samples
obtained by being used to primers such as D6S251,
D6S275, D6S301, D6S474, D6S1039, ARG1, D6S1038,
D6S441 and D6S1008 primers on the long arm (q) of
chromosome 6, and D9S169, D9S126 and D9S171 prim-
ers on the short arm (p) of chromosome 9 were amplified
by PCR. Localizations of primer and primer series on the
chromosomes were obtained from Genome Database
[12].
2.2. PCR and LOH analysis
PCR was used to amplify genomic DNA in a 25-μl reaction
volume containing 2.5 μl 10× Buffer (2 M Tris bas; 1.14
ml glacial ascetic acid; 0.5 M Na2EDTA), 1.5 μl MgCl2 (25
mM), 1 μl dNTP (2.5 mM), 1 μl forward primer (20 ng/
μl) and 1 μl reverse primer (20 ng/μl), 0.1 μl Taq DNA
Polymerase (5U/μl), 1 μl genomic DNA and 16.9 μl
dH2O. PCR was performed in an MJ Research PTC-100
programmable thermal controller. Conditions for the
amplification of D6S251, D6S1038, D6S441, D9S126
and D9S169 primers consisted of an initial denaturation
for 3 min at 94°C, followed by 32 cycles: 30 sec at 94°C,
30 sec at 53°C and 30 sec at 72°C, and then by a 3 min
extension at 72°C. Conditions for the amplification ofJournal of Carcinogenesis 2006, 5:23 http://www.carcinogenesis.com/content/5/1/23
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D6S275, D6S301, D6S474, D6S1039, ARG1, D6S1008
and D9S171 primers consisted of an initial denaturation
for 3 min at 94°C followed by 32 cycles: 30 sec at 94°C,
30 sec at 55°C and 30 sec at 72°C, and then by a 3 min
extension at 72°C.
PCR products were diluted 1:1 with a 95% formamide gel-
loading buffer. Following denaturation at 94°C for 3 min,
7  μl of each sample were size fractionated by electro-
phoresis through 6% polyacrylamide sequencing gel by
1600 volt current for 3 hours. Silver nitrate dying was
applied to gels after electrophoresis and they were photo-
graphed with an Automatic Processor Compatible (APC).
The allelic patterns obtained from pleural effusions and
blood genomic DNAs were compared. One allelic loss in
heterozygote individuals was accepted as LOH. LOH was
considered to have occurred when there was evidence of 2
alleles in the control DNA and complete loss of an allelic
band in the pleural effusion DNA, or when the allelic ratio
in pleural effusion DNA differed by a factor greater than
1.6 from the corresponding allelic ratio in control DNA.
The intensity of allelic bands was determined by densit-
ometry (NIH Image software, version 1.59).
Results
Duration of environmental asbestos exposure was not sig-
nificantly different in the male (mean 27.2 ± 11.2 y) and
female (mean 27.4 ± 6.9 y) patients of the study group (p
> 0.05). Some demographic features of the patient group
are shown in Table 1.
Comparative molecular studies of 4 patients were not
completed: DNA material could not be obtained from
patient 15 and patient 16 due to excessive hemorrhagic
pattern of pleural fluid samples, and levels of DNA mate-
rials obtained from the blood of patient 7 and pleural
fluid of patient 17 were not sufficient.
Totally 12 regions selected as 9 regions on chromosomes
6 and 3 regions on chromosomes 9 for LOH analysis. Of
the 13 cases of which pleural effusion and blood genomic
DNA were compared, 7 (54%) showed allelic loss in 6q.
The extent of the partial deletions was used to define 4 dis-
crete minimal regions of nonoverlapping deletion, short-
est region overlap 1, 2, 3 and 4 (SRO1, SRO2, SRO3 and
SRO4).
The boundaries of the most centromeric region of dele-
tion, SRO1, were defined by marker D6S251 proximally
and by D6S249 distally. These represented a region of ~9
cM within 6q14-21. Allelic losses affecting SRO1 were
detected in 1 of 13 (8%) MPMs analyzed. SRO2 was
deleted in 3 of 13 cases (23%). The distance between
D6S301 and D6S474 was ~8 cM, and D6S301 was local-
ized to 6q16.3-21. The 3rd  minimally deleted region,
SRO3 was defined by an interstitial deletion in 4 of 13
cases (31%). SRO3 was flanked by D6S1039 proximally
and by D6S1038 distally. These 2 markers, which are sep-
arated by ~10 cM, reside within 6q21-23.2. A 4th discrete
region of deletion, SRO4, was defined proximally by the
terminal deletion in cases 2, 6 and 10, and distally by
deletion in none. SRO4 lies between D6S441 and
D6S1008, a region of ~13 cM. Losses affecting this region
were observed in 3 cases (23%). On the basis of the posi-
tion of markers adjacent to D6S441 and D6S1008, SRO4
was probably located within band 6q25.
Table 1: Malignant pleural, mesothelioma patient characteristics
Patient No Age Sex Environmental Asbestos 
Exposure Period (y)
15 2 M a l e 2 5
26 1 M a l e 2 0
37 7 M a l e 4 0
46 6 M a l e 2 0
57 5 F e m a l e 4 0
65 4 F e m a l e 2 0
75 8 F e m a l e 1 8
85 6 M a l e 2 5
96 4 F e m a l e 3 0
10 50 Male 50
11 55 Female 30
12 52 Male 20
13 53 Male 15
14 48 Female 25
15 67 Male 30
16 75 Female 30
17 65 Female 26Journal of Carcinogenesis 2006, 5:23 http://www.carcinogenesis.com/content/5/1/23
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Of a total of 117 alleles, which were determined by 9 pol-
ymorphic determinant for chromosome 6 in 13 patients,
90 (77%) were found to be heterozygote and 27 (23%)
homozygote. Individual cases exhibited either a single
SRO or more than one SRO (Table 2). Loss of SRO1 alone
was not observed. Loss of SRO2 alone was detected in case
12. Losses of both SRO1 and SRO4 were detected in one
case (case 2). SRO2 and SRO3 were both lost in case 1.
SRO2 and SRO4 were both lost in case 10. Losses of both
SRO3 and SRO4 were detected in one case (case 6) (Fig.
1).
In 13 patients, of 39 alleles which were determined by 3
markers for 9th chromosome, 18 (46%) were heterozygote
and 21 (54%) were homozygote. No LOH case was deter-
mined with D9S171, D9S126 and D9S169 markers on 9p
(Table 3).
Discussion
MPM was observed in 2–10 % of people who had been
exposed to high doses of asbestos [6]. The estimated inci-
dence of MPM has been reported to be 43 per million
inhabitants in the southeast of Turkey [13]. In asbestos
polluted areas of eastern and south-eastern parts of Tur-
key, mainly tremolite type fibrous mineral exposure was
seen [2,14]. The reason for the relative rarity of distant
metastases may be related to the rapidity of tumor growth,
which generally results in death within 9–10 months after
diagnosis. Therapeutic results remain poor and cure of the
disease is exceptional [15,16]. Unusually long survival
without any treatment is, however, occasionally observed
[8].
Epidemiological studies and case reports have revealed
that inhaled asbestos dust also increases the frequency of
extra pulmonary cancers. The frequency of this kind of
pathologies increases with the risk of asbestos exposure.
This increase has been determined as 6 times in gastric
cancer and 3 times in colon cancer [2,5].
Although there is no common specific chromosomal
alteration in MPM patients, inactivation and/or loss of
TSG caused by frequent cytogenetic deletions of MPM are
thought to be responsible in neoplastic development and
progression of mesothelial cells [11]. Complex profiles of
characteristic somatic-genetic alterations of MPM show
that tumorigenesis of this malignancy is a multi-direc-
tional and multi-step period. Karyotype and comparative
genomic hybridization analysis of MPM show the pres-
ence of deletions in specific regions of 1p, 3p, 6q, 7p, 7q,
9p, 13q, 15q, 17p and 22q chromosome arms [6,12,17].
In MPM, the common sites of allelic losses were in 4 dif-
ferent regions, including 6q14-q21 (SRO1), 6q16.3-q21
(SRO2), 6q21-q23.2 (SRO3) and 6q25 (SRO4) localiza-
tions on 6q, and 9p21-p22 region of chromosome 9
[6,11,12]. Loss of function of one or more TSG, deter-
mined by LOH at 6q, is interpreted as an important
genetic change which contributes development of this
malignancy [12].
Bell et al. found higher frequency of losses in 6q (61%)
than previously reported ratios (40%) [12]. In our study,
LOH was found in at least one site in 7 (54%) of 13
patients. We examined 117 alleles on chromosome 6 and
found 90 (77%) of them heterozygote and 27 (23%)
homozygote. If we look at the number of examined mark-
ers and study material, the ratios we obtained were as suc-
cessful as other reports on this subject. However, the
results of other related studies were derived from DNA
Table 2: Allelic features and LOH regions found at chromosome 6 in patient group.
Pat. No Primers
D6S251 D6S275 D6S301 D6S474 D6S1039 ARG1 D6S1038 D6S441 D6S1008
1---+ - + ±--
2-+ ±± -±± - +
3---- -± ± - -
4±±±± -±+ -±
5±±-± --+ --
6±-±- -+ --+
8---- ± -- - -
9---- --- - -
10 ± - ± + -±- ± +
11 - - ± - - - - - -
12 ± - + -- - ---
13 - - ± - - - - - -
1 4 ---- --- ± -
Pat.: Patient, +: Allelic loss, -: retention of heterozygosity, ± : constitutive homozygosity uninformative. (Due to inability to perform essential PCR 
analysis patient 7 was not included in the table.)Journal of Carcinogenesis 2006, 5:23 http://www.carcinogenesis.com/content/5/1/23
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samples obtained from tumor derived cell lines. Also it is
possible to increase the sensitivity of molecular studies by
using DNA extraction from pleural fluid because it is easy,
has a low risk profile, and can be repeated rapidly.
Allelic losses for SRO1 were detected in 1 of 13 (8%).
SRO2 was also deleted in 3 of 13 cases (23%). SRO3 was
defined by an interstitial deletion in 4 of 13 cases (31%),
whereas SRO4 was defined in 3 cases (23%).
Recent studies have showed that, in MPM, p16/CDKN2A
with 9p21 deletions is an important TSG [11]. Although
some important TSG losses in 6q and 9p, which may have
an important effect in the development of this malignity,
have been reported, the presence of TSG losses at 6q in the
early stages of MPM and 9p in advanced stage of MPM are
stressed [17].
Although we had determined possible TSG losses at
SRO1, SRO2, SRO3 and SRO4 sites of chromosome 6, our
inability to determine a loss in p16CDKN2 TSG at region
of 9p may be due to the early stages of disease in our
patients. Thus, determination of changes that may appear
in these 2 chromosomes in the early stages of MPM
became a secondary benefit in our study.
Moreover, of 39 alleles of the 13 patients, which were
determined with 3 markers for chromosome 9, 18 (46%)
were found heterozygote and 21 (54%) were found
homozygote. D9S126 was uninformative in all of our
cases.
Three or 4 SRO sites of genomic loss from 6q have also
been described in other malignancy types, such as breast
cancer [18], ovary cancer [19], and Non-Hodgkin's lym-
phoma [6,11]. In DNA analysis, deletions of interferon
locus at 9p21-p22 were also detected in acute lymphob-
lastic leukemia, glioma, melanoma, lung cancer and blad-
der cancer [6]. Oncology-consultant research showed no
presence of any different tumor.
LOH at p53 TSG accelerates tumor progression [20]. In
malignant mesothelioma, it was hypothesized that it may
Representative autoradiographs showing allelic band patterns  at critical breakpoints that define four minimal regions of  deletion of 6q in MPM Figure 1
Representative autoradiographs showing allelic band patterns 
at critical breakpoints that define four minimal regions of 
deletion of 6q in MPM. It is defined retention of heterozygos-
ity at D6S1008, D6S1038 and D6S251 in case 3, 6 and 11, 
respectively. Allelic loss at D6S1008 in case 2, 6 and 10; 
D6S275 in case 2; D6S474 in case 1 and 10; D6S1038 in case 
4 and 5; ARG1 in case 6; D6S301 in case 12. Case numbers 
are shown under the each autoradiograph. Alleles recognized 
by microsatellite markers are indicated (●). Arrowheads, 
LOH. B (above panels), normal DNA from peripheral blood; 
E, pleural effusion DNA.
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Table 3: Allelic characteristics found at chromosome 9p in 
patient group.
Patient No Primers
D9S171 D9S126 D9S169
1- ± -
2 ±±±
3± ± -
4- ± -
5± ± -
6 ±±±
8- ± -
9± ± -
10 - ± -
11 - ± -
12 - ± -
13 ± ± -
14 - ± -
+: allelic loss, -: retention of heterozygosity, ± : constitutive 
homozygosity uninformative. (Due to inability to perform the 
essential PCR analysis patient 7 was not included in the table.)Journal of Carcinogenesis 2006, 5:23 http://www.carcinogenesis.com/content/5/1/23
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be inactivated by SV40 (simian virus 40) large T antigen
(SV40 Tag) [21,22]. SV-40 virus increases the sensitivity of
human mesothelial cells against asbestos, causes pheno-
typic changes and oncogenic transformations in asbestos
related lesions, and also, in some rare cases without any
relation to asbestosis with malignant transformation, may
cause mesothelioma [11]. In the tissue samples derived
from MPM patients who had been exposured to asbestos
or erionite, no SV40 DNA was found. The reason for this
may be because SV40 contaminated vaccines are not used
in Turkey [23].
In conclusion, in our study, in patients with MPM,
genomic losses at 6q were common, and 4 SRO sites with
6q14-21, 6q16.3-21, 6q21-23.2 and 6q25 deletions were
determined. The inability to determine LOH at 9p was
explained because of the early stage of MPM of our cases.
In our study, contrary to present literature studies on this
subject, instead of taking samples from tumor tissue and
tumor derived cell lines, we used DNA obtained from
pleural fluid which was isolated by thoracentesis. This
method is faster, less invasive and more practical than
other methods. Molecular genetic clues obtained with
more detailed mapping of TSGs in MPM patients may also
be collimator for studies aimed at risk, pathogenesis, early
diagnosis and treatment of the disease.
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